Search
 
Update

AARP backs HHS: Keep Medicare drug price negotiations on track, dismiss lawsuit

The nation’s leading lobbying group for seniors filed an amicus brief on Monday in Washington, D.C., urging a federal court to dismiss a lawsuit filed by Merck to challenge Medicare’s Drug Price Negotiation Program.

By Alan Goforth | September 20, 2023 at 12:21 PM
AARP headquarters in Washington, D.C.

Leading interest groups continue to stake out positions on the Medicare Drug Price Negotiation Program, which aims to save $25 billion annually by 2031 through price negotiations for drugs that are most costly to Medicare.

The AARP and AARP Foundation on Monday filed an amicus brief urging the U.S. District Court for the District of Columbia to dismiss Merck & Co.’s lawsuit challenging the program. The brief supports the U.S. Department of Health and Human Services against Merck, the manufacturer of type 2 diabetes medicine Januvia. It said the drug’s list price has jumped more than 275% since entering the market in 2006 and has accounted for $21.6 billion in Medicare Part D spending between 2017 and May 2023.

Complete your profile to continue reading and get FREE access to BenefitsPRO.com, part of your ALM digital membership.

Your access to unlimited BenefitsPRO.com content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical BenefitsPRO.com information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com

Already have an account?

NOT FOR REPRINT

© 2023 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Recommended Stories

New COVID variant is on the rise, has tripled in the past 2 weeks

New COVID variant is on the rise, has tripled in the past 2 weeks

Alan Goforth |

Although the pandemic is over, COVID-19 remains a persistent threat, as incidents of a highly mutated variant, BA.2.86, have tripled in the past 2 weeks but the CDC is confident the vaccines will be effective against the new strain.

BenefitsPRO Broker Expo 2024Event

The premier educational and networking event for employee benefits brokers and agents.

Get More Information
 

BenefitsPRO Broker Expo 2024Event

The premier educational and networking event for employee benefits brokers and agents.

Get More Information
 

BenefitsPRO

Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2023 ALM Global, LLC. All Rights Reserved.